This is a preview of subscription content, log in via an institution to check access.
References
Danilovski A. Quo vadis generic pharmaceutical industry? [evening plenary session]. 37th European Symposium on Clinical Pharmacy; 2008 Oct 21–24; Dubrovnik, Croatia
Zarb-Adami M. The balancing act and therapeutic costs [plenary session 1.1]. 37th European Symposium on Clinical Pharmacy; 2008 Oct 21–24; Dubrovnik, Croatia
Stuart M. Clinical evidence in therapeutic innovations [plenary session 1.2]. 37th European Symposium on Clinical Pharmacy; 2008 Oct 21–24; Dubrovnik, Croatia
Simoens, S. Economic evaluation of pharmacy practice [plenary session 1.3]. 37th European Symposium on Clinical Pharmacy; 2008 Oct 21–24; Dubrovnik, Croatia
Schneider P. The diffusion of innovations: which technology to chose [plenary session 2.1]. 37th European Symposium on Clinical Pharmacy; 2008 Oct 21-24; Dubrovnik, Croatia
Hudson S. Skills required to prepare for the changing risks in medicine safety [plenary session 3.1]. 37th European Symposium on Clinical Pharmacy; 2008 Oct 21–24; Dubrovnik, Croatia
Wright P, Anoniou S, Khachi H, et al. Pharmacist involvement in a multidisciplinary clinic for elective percutaneous coronary intervention (PCI) patients: results for first 1000 patients seen. [poster PC-21]. 37th European Symposium on Clinical Pharmacy; 2008 Oct 21-24; Dubrovnik, Croatia: 28
Arjakse J, Kongi K, Marandi T. Evaluation of deep venous thrombosis prophylaxis with nadroparin in surgical wards of North Estonia Medical Centre foundation [poster PT-12]. 37th European Symposium on Clinical Pharmacy; 2008 Oct 21224; Dubrovnik, Croatia: 99
Rights and permissions
About this article
Cite this article
News from the 37th European Symposium on Clinical Pharmacy; 21–24 October 2008; Dubrovnik, Croatia. Drugs Ther. Perspect 25, 24–26 (2009). https://doi.org/10.2165/0042310-200925010-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/0042310-200925010-00007